Home > Insider Trading > Filing (0001140361-14-031039)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1581720	Loxo Oncology Inc.	LOXO	Pharmaceutical Preparations (2834)	462996673

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1120478	Md A Dov Goldstein	C/O Loxo Oncology, Inc. One Landmark Square, Suite 1122 Stamford CT 06901	Cfo And Treasurer	Yes	Yes	Yes	No
1172252	N Andrew Schiff	888 Seventh Avenue, 30Th Fl New York NY 10106		No	No	Yes	No
1250195	Steve Elms	888 Seventh Avenue 30Th Floor New York NY 10106		Yes	No	Yes	No
1297291	J Dennis Purcell	888 Seventh Avenue, 30Th Fl New York NY 10106		No	No	Yes	No
1444717	Aisling Capital Iii Lp	888 Seventh Avenue, 30Th Fl New York NY 10106		No	No	Yes	No
1532634	Aisling Capital Partners Iii Lp	Aisling Capital Llc 888 Seventh Avenue 30Th Floor New York NY 10106		No	No	Yes	No
1532635	Aisling Capital Partners Iii Llc	Aisling Capital Llc 888 Seventh Avenue 30Th Floor New York NY 10106		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-06	2,850,709	$0.00	3,039,416	No	4	C	Direct
Common Stock	Acquisiton	2014-08-06	413,077	$13.00	3,452,493	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2014-08-06	2,343,749	$0.00	2,343,749	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2014-08-06	506,960	$0.00	506,960	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. All shares of Common Stock issued upon conversion were aggregated.
The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, and Dr. Dov Goldstein, the Issuer's Chief Financial Officer and Treasurer, are each a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms and Dr. Goldstein are members of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.
None.